Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

Johnson & Johnson is contributing $1 million to support the development of curricula and modernization of training and lab ...

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics and headquartered in Switzerland, ...

NHS approves £1.65m gene therapy for sickle cell disease, offering a potential cure. A milestone for patients, especially in ...

A research team from Nagoya University Graduate School of Medicine has made a major discovery on how the CUL5 gene affects ...

MaxCyte, Inc., a leading, cell-engineering focused company providing solutions to advance the discovery, development and commercialization of next-generation cell therapeutics announced today the ...

CDMO Rentschler Biopharma is signalling its intent to cut down cell and gene therapy operations by shutting down its UK ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in England. About 50 people a year with the inherited blood disorder are likely to ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

A GROUNDBREAKING genetic treatment with the potential to cure sickle cell disease will be rolled out on the NHS. The one-off ...

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...